Clinical Study on Huatan Tongluo Decoction for Intravascular Treatment of Acute Cerebral Infarction and Reperfusion
Objective:To observe the reperfusion of Huatan Tongluo Decoction for intravascular treatment of acute cerebral infarction.Method:A total of 60 patients with acute cerebral infarction who received intravascular treatment in Yangjiang Hospital of Traditional Chinese Medicine from August 2022 to September 2023 were selected.They were divided into control group and intervention group according to random number table method,with 30 cases in each group.The control group was given routine treatment,intervention group was given Huatan Tongluo Decoction on the basis of control group.Blood lipid indexes,related indexes,neurological function,traditional Chinese medicine syndrome scores before and after treatment,clinical efficacy and safety were compared between the two groups.Result:After treatment,the levels of total cholesterol(TC),triglyceride(TG)and low density lipoprotein cholesterol(LDL-C)in the intervention group were lower than those in the control group,the differences were statistically significant(P<0.05).After treatment,the levels of fibrinogen(FIB),D-dimer(D-D),C-reactive protein(CRP)in the intervention group were lower than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the national institutes of health stroke scale(NIHSS)score and traditional Chinese medicine syndrome score in the intervention group were lower than those in the control group,and the differences were statistically significant(P<0.05).The total effective rate of the intervention group was higher than that of the control group,and the difference was statistically significant(P<0.05).No serious adverse reactions occurred in both groups during treatment.Conclusion:Huatan Tongluo Decoction is effective in the intravascular treatment of patients with acute cerebral infarction,and can reduce the levels of blood lipid,FBI,D-D and CRP.